Outlook Therapeutics’ (OTLK) Buy Rating Reaffirmed at HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $30.00 price target on the stock.

OTLK has been the subject of a number of other reports. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research lowered their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.73.

Outlook Therapeutics Trading Down 4.8 %

NASDAQ OTLK opened at $2.19 on Friday. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85. The company has a 50 day moving average of $2.78 and a 200-day moving average of $5.39. The firm has a market cap of $54.55 million, a price-to-earnings ratio of -0.24 and a beta of 0.53.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06. On average, analysts forecast that Outlook Therapeutics will post -2.33 earnings per share for the current year.

Institutional Trading of Outlook Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its position in Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the period. Geode Capital Management LLC raised its stake in shares of Outlook Therapeutics by 49.2% during the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after buying an additional 112,812 shares during the last quarter. XTX Topco Ltd acquired a new position in Outlook Therapeutics in the third quarter valued at approximately $199,000. State Street Corp boosted its stake in Outlook Therapeutics by 10.0% in the third quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after acquiring an additional 21,201 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Outlook Therapeutics by 55.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after acquiring an additional 18,287 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.